Printer Friendly

GLAXO INC. RECEIVES CLEARANCE TO MARKET IMITREX INJECTION

 RESEARCH TRIANGLE PARK, N.C., Dec. 29 /PRNewswire/ -- Cerenex Pharmaceuticals, a division of Glaxo Inc., announced today that it has received clearance from the U.S. Food and Drug Administration to market Imitrex (sumatriptan succinate) Injection, a new medication given by subcutaneous injection (beneath the skin) for the acute treatment of migraine.
 Imitrex will be available to consumers by prescription in late March 1993.
 "Migraine takes a tremendous toll on the sufferer's quality of life," said Roger Cady, M.D., medical director, Shealy Institute for Comprehensive Care in Springfield, Mo. "Many people are so debilitated by their symptoms that they are unable to carry on with their personal lives and professional responsibilities."
 In clinical studies, migraine sufferers treated with Imitrex started to experience relief within 10 minutes, and 70 percent had complete or near complete relief within one hour. Unlike other medications used for migraine, Imitrex is effective when taken at any point during a migraine attack. In addition, it is the only migraine medication that treats the total symptom complex: pain, nausea, vomiting and light and sound sensitivity.
 Imitrex is the first highly selective serotonin-agonist effective in treating migraine. Serotonin is a naturally occurring neurotransmitter that plays a role in several biological functions in the body. Imitrex acts by selectively constricting blood vessels in the head, which are thought to be dilated and distended during a migraine attack.
 "This approval represents the culmination of nearly 20 years of original Glaxo research," said Charles A. Sanders, M.D., chairman and chief executive officer of Glaxo Inc., the U.S. subsidiary of Glaxo Holdings p.l.c. "Imitrex offers new hope to people who suffer from this debilitating and previously inadequately treated disease," he added.
 According to current estimates, more than 11 million Americans suffer from migraine with moderate to severe disability. Migraine is characterized by multiple symptoms, including recurrent pain on one or both sides of the head and one or more of the following: nausea, vomiting and sensitivity to bright light and sound. The incapacitating attacks last from four to 72 hours. About 15 percent of migraine attacks are preceded by visual disturbances known as aura.
 Subcutaneous Imitrex Injection has been clinically studied in more than 6,000 patients worldwide, involving over 10,000 migraine attacks. Most side effects observed in clinical trials were mild and short-lived. In general, some patients experienced an injection site reaction involving pain, stinging or burning that usually lasts only a few minutes, or feelings of flushing and dizziness, warmth, heaviness and pressure and tingling or tightness in various parts of the body, including the chest. (NEJM; August 1, 1991, Vol. 325, pg. 320)
 Imitrex should not be used in patients with uncontrolled high blood pressure or known or suspected heart disease. As with any prescription medication, rare side effects may occur, and patients should consult their physician regarding appropriate use.
 Imitrex is administered by subcutaneous injection and is packaged with a unique push-button autoinjector for convenient self-administration. Price will be announced at availability.
 The new medication is currently available in more than 25 countries, including Canada, U.K., Holland and Italy.
 Glaxo Inc. researches, develops, manufactures and markets prescription medicines, including those for the treatment of gastrointestinal, respiratory, central nervous system and cardiovascular diseases, and infections, as well as diseases of the skin. It is a subsidiary of London-based Glaxo Holdings p.l.c. (NYSE: GLX).
 -0- 12/29/93
 /CONTACT: Rick Sluder of Glaxo Inc., 919-248-2839/
 (GLX)


CO: Glaxo Inc. ST: North Carolina IN: MTC SU: PDT

TS -- NY021 -- 0346 12/29/92 13:14 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 29, 1992
Words:594
Previous Article:THE TAIWAN FUND, INC. ANNOUNCES INVESTMENT PERFORMANCE
Next Article:WEIGHT WATCHERS IS ALL-NEW FOR 1993; REDESIGNED PLAN, HIGH-TECH MEETING ENVIRONMENT PROVE 'IT'S NOT YOUR MOTHER'S WEIGHT LOSS PROGRAM'
Topics:


Related Articles
ADENOSCAN RECEIVES MARKETING CLEARANCE IN UNITED KINGDOM; PRODUCT TO BE MARKETED BY SANOFI PHARMA
GLAXO INC. RECEIVES CLEARANCE TO MARKET IMITREX(R) TABLETS IN U.S.
IMITREX(R) TABLETS NOW AVAILABLE FOR PEOPLE WITH MIGRAINE IN THE U.S. FIRST HIGHLY SELECTIVE MIGRAINE THERAPY IN TABLET FORM
New Self-Administration Device For Imitrex(R) Injection; Now Available By Proscription In The United States
Latest Clinical, Socioeconomic Data on Migraine Medications Presented by Glaxo Wellcome at Scientific Meeting
Glaxo Wellcome Inc. Receives Clearance to Market Imitrex(R) Nasal Spray in the U.S.
Imitrex(R) Nasal Spray Now Available for People With Migraine in the U.S.
Glaxo Wellcome Inc. Receives Clearance to Market Amerge(TM) (Naratriptan Hydrochloride) Tablets in U.S.
Productivity Studies Show Migraine Sufferers Get Back To Work More Quickly With Imitrex Injection
Studies Show Imitrex Provides Fast, Consistent Relief For Migraine Sufferers

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters